These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34117988)

  • 1. Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data.
    Marcellusi A; Mennini FS; Sciattella P; Favato G
    Eur J Health Econ; 2021 Dec; 22(9):1371-1379. PubMed ID: 34117988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study.
    Cocchio S; Baldovin T; Bertoncello C; Buja A; Furlan P; Saia M; Baldo V
    BMC Infect Dis; 2017 Apr; 17(1):249. PubMed ID: 28381294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007-2018).
    Cocchio S; Prandi GM; Furlan P; Bertoncello C; Fonzo M; Saia M; Baldovin T; Baldo V
    BMC Infect Dis; 2020 Nov; 20(1):857. PubMed ID: 33208109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
    Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Rodrigo-Casares V; Orrico-Sánchez A
    Vaccine; 2022 Jan; 40(2):316-324. PubMed ID: 34865874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The burden of HPV-related diseases in Italy, 2001-12.
    Kuhdari P; Previato S; Giordani M; Biavati P; Ferretti S; Gabutti G
    J Public Health (Oxf); 2017 Dec; 39(4):730-737. PubMed ID: 28334854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group.
    Marcellusi A; Capone A; Favato G; Mennini FS; Baio G; Haeussler K; Bononi M;
    Clin Ther; 2015 Jan; 37(1):156-167.e4. PubMed ID: 25487083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
    Bonanni P; Gabutti G; Demarteau N; Boccalini S; La Torre G
    BMC Infect Dis; 2015 Sep; 15():377. PubMed ID: 26381489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HPV vaccination: health gains in the Italian female population.
    Marcellusi A
    Popul Health Metr; 2017 Sep; 15(1):36. PubMed ID: 28962572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and cost of cervical cancer care and prevention in Apulia (Italy), 2007/2016.
    Bianchi FP; Gallone MS; Fortunato F; Boccalini S; Martinelli D; Prato R; Tafuri S
    Ann Ig; 2018; 30(6):490-501. PubMed ID: 30614498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
    Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
    J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.
    Dehlendorff C; Baandrup L; Kjaer SK
    J Natl Cancer Inst; 2021 Jul; 113(7):869-874. PubMed ID: 33377930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study.
    Martellucci CA; Morettini M; Brotherton JML; Canfell K; Manzoli L; Flacco ME; Palmer M; Rossi PG; Martellucci M; Giacomini G; D'Errico MM; Pasqualini F
    Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):588-594. PubMed ID: 35027435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
    Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
    BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
    Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
    Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
    Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
    Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.